Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort-Reference-Cited by-同舟云学术

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

Published:2021-10-10 Issue: Volume: Page:
ISSN:2688-4526
Container-title:BJUI Compass
language:en
Short-container-title:BJUI Compass

Author:

Khoshkar Yashar¹^ORCID,Westerberg Marcus²³^ORCID,Adolfsson Jan⁴^ORCID,Bill‐Axelson Anna³^ORCID,Olsson Henrik⁵^ORCID,Eklund Martin⁵^ORCID,Akre Olof¹⁶^ORCID,Garmo Hans³⁷⁸^ORCID,Aly Markus¹⁶^ORCID

Affiliation:

1. Department of Molecular Medicine and Surgery Karolinska Institute Stockholm Sweden

2. Department of Mathematics Uppsala University Uppsala Sweden

3. Department of Surgical Sciences Uppsala University Uppsala Sweden

4. Department of Clinical Science, Intervention and Technology Karolinska Institute Stockholm Sweden

5. Department of Medical Epidemiology and Biostatistics Karolinska Institute Stockholm Sweden

6. Prostate Cancer Flow, Patient Area Pelvic Cancer Karolinska Sjukhuset Solna Stockholm Sweden

7. Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences King's College London London UK

8. Regional Cancer Centre, Division of Central Sweden Uppsala Sweden

Funder

Kommunfullmäktige, Stockholms Stad

Cancerföreningen i Stockholm

Centre for Interdisciplinary Mathematics, Uppsala Universitet

Publisher

Wiley

Subject

Religious studies,Cultural Studies

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bco2.116

Reference32 articles.

1. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

2. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

4. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

5. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-11-07

2. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics;World Journal of Urology;2023-05-09

3. Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate Cancer;2023-04-21

4. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling;Proceedings of the National Academy of Sciences;2023-04-17

5. Potential role for protein kinase D inhibitors in prostate cancer;Journal of Molecular Medicine;2023-02-27